Skip to main content

Obstruktive Lungenerkrankungen im Alter – Asthma und COPD

  • Chapter
  • First Online:
Geriatrische Notfallversorgung
  • 3829 Accesses

Zusammenfassung

Die größte Herausforderung der nächsten Jahre ist die zunehmende Alterung der Bevölkerung. Obstruktive Lungenerkrankungen zählen zu den häufigsten Erkrankungen, und alleine die COPD (chronisch-obstruktive Lungenerkrankung) wird die vierthäufigste Todesursache im Jahr 2020 sein. Die Häufigkeit der obstruktiven Erkrankungen wird für die COPD mit 10–25 % der über 60- bis 70‑Jährigen, für das Asthma mit ca. 10 % der über 65‑Jährigen und für unklare Dyspnoe zusätzlich mit 15 % angegeben [1]. Die Zahlen der COPD in Österreich überschreiten diese Werte deutlich: mit einer Prävalenz von bis zu 50 % der über 70‑Jährigen [2], [3]. Asthma bronchiale, insbesondere allergisches Asthma, ist beim älteren Patienten unterdiagnostiziert und auch untertherapiert, wobei wir von ca. 10 % der älteren Bevölkerung ausgehen müssen.

Die COPD ist die häufigste obstruktive Lungenerkrankung des Alters, und die Prävalenz steigt auch mit dem Alter und mit der Exposition zu Tabakrauch und anderen inhalativen Noxen. Im Unterschied zum Asthma wird die COPD anhand der Spirometrie klassifiziert und nach den GOLD Kriterien entsprechend behandelt [4]. Dies unabhängig von der bestehenden Symptomatik.

Alter per se verschlechtert den Gesundheitszustand von COPD nicht, altersabhängige Faktoren wie soziale Isolation oder Immobilität verschlechtern den Allgemeinzustand bei bestehender COPD sehr wohl [5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Viegi G, Maio S, Simoni M et al (2009) The epidemiological link between ageing and respiratory diseases. Eur Resp Mon 43:1–17

    Google Scholar 

  2. Schirnhofer L, Lamprecht B, Vollmer WM et al (2007) COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest 131:29–36

    Article  PubMed  Google Scholar 

  3. Buist AS, McBurnie MA, BOLD Collaborative Research Group, Vollmer WM et al (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370:741–750

    Article  PubMed  Google Scholar 

  4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011) Global Strategy for the diagnosis, management and prevention of COPD. Available from: http://www.goldcopd.org

    Google Scholar 

  5. Antonelli Incalzi R, Pistelli R, Sa.R.A. Study Group, Imperiale C et al (2004) Effects of chronic airway disease on health status of geriatric patients. Aging Clin Exp Res 16:26–33

    Article  PubMed  Google Scholar 

  6. Bellia V, Scichilone N, Battaglia S (2009) Asthma in the elderly. Eur Resp Mono 43:56–76

    Google Scholar 

  7. Bellia V, Pedone C, Catalano F et al (2007) Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest 132:1175–1182

    Article  PubMed  Google Scholar 

  8. Weiner P, Magadle R, Waizman J et al (1998) Characteristics of asthma in the elderly. Eur Resp J 12:564–568

    Article  CAS  Google Scholar 

  9. Global Strategy for Asthma Management and Prevention, revised version 2010, Global Inititiative for Asthma, GINA-report 2010, www.ginaasthma.org

    Google Scholar 

  10. Rabe KF, Beghé B, Luppi F, Fabbri LM (2007) Update in chronic obstructive pulmonary disease 2006. Am J Resp Crit Care Med 175(12):1222–1232

    Article  CAS  PubMed  Google Scholar 

  11. Fletcher MJ, Upton J, Taylor-Fishwick J et al (2011) MC. Public Health 11:612

    PubMed  PubMed Central  Google Scholar 

  12. Buist AS, McBurnie MA, BOLD Collaborative Research Group, Vollmer WM et al (2012) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 380(9844):806

    Article  Google Scholar 

  13. Jemal A, Ward E, Hao Y, Thun M (2005) Trends in the leading causes of death in the United States. JAMA 294(10):1255–1259

    Article  CAS  PubMed  Google Scholar 

  14. Murray CJL, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349(9064):1498–1504

    Article  CAS  PubMed  Google Scholar 

  15. Bestall JC, Paul EA, Garrod R et al (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54:581–586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jones PW, Harding G, Berry P et al (2009) Development and first validation of the COPD Assessment Test. Eur Respir J 34:648–654

    Article  CAS  PubMed  Google Scholar 

  17. Renewing Health Project. Data in publication.

    Google Scholar 

  18. Decramer M, Celli B, Kesten S et al (2009) Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374:1171–1178

    Article  CAS  PubMed  Google Scholar 

  19. Hurst JR, Vestbo J, Anzueto A et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138

    Article  CAS  PubMed  Google Scholar 

  20. Celli BR, Cote CG, Marin JM et al (2004) The Body-Mass Index, Airflow Obstruction, Dyspnoea, and Exercise Capacity Index in chronic obstructive pulmonary disease. NEJM 350:1005–1012

    Article  CAS  PubMed  Google Scholar 

  21. Antonelli-Incalzi R, Imperiale C, SaRA Investigators, Bellia V et al (2003) Do GOLD stages of COPD severity really correspond to differences in health status? Eur Resp J 22:444–449

    Article  CAS  Google Scholar 

  22. O’Donnell DE, Revill SM, Webb KA (2001) Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:770–777

    Article  PubMed  Google Scholar 

  23. Antonelli-Incalzi R (2009) Eur Resp Mono 43:35–55

    Google Scholar 

  24. Miravitles M (2009) Eur Respir Mon 43:90–110

    Google Scholar 

  25. Dahl R, Greefhorst LA, Nowak D et al (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:778–784

    Article  CAS  PubMed  Google Scholar 

  26. Mahler DA, Donohue JF, Barbee RA et al (1999) Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115:957–965

    Article  CAS  PubMed  Google Scholar 

  27. Dusser D, Bravo ML, Iacono P (2006) The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27:547–555

    Article  CAS  PubMed  Google Scholar 

  28. Tashkin DP (2010) Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Current opinion in pulmonary medicine 16:97–105

    Article  CAS  PubMed  Google Scholar 

  29. O’Donnell DE, Fluge T, Hamilton A et al (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23:832–840

    Article  PubMed  Google Scholar 

  30. Casaburi R, Mahler DA, Jones PW et al (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217–224

    Article  CAS  PubMed  Google Scholar 

  31. Niewoehner DE, Rice K, Cote C et al (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143:317–326

    Article  CAS  PubMed  Google Scholar 

  32. Casaburi R, Kukafka D, Cooper CB et al (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127:809–817

    Article  CAS  PubMed  Google Scholar 

  33. Tashkin DP, Celli B, Senn S et al (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543–1554

    Article  CAS  PubMed  Google Scholar 

  34. Singh S, Loke YK, Enright PL, Furberg CD (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342

    Google Scholar 

  35. Rossi A, Kristufek P, Levine BE et al (2002) Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121:1058–1069

    Article  CAS  PubMed  Google Scholar 

  36. Tashkin DP, Fabbri LM (2010) Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 11:149

    Article  PubMed  PubMed Central  Google Scholar 

  37. Calverley PM, Anderson JA, Celli B et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–778

    Article  CAS  PubMed  Google Scholar 

  38. Donohue JF, Fogarty C, Lotvall J et al (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182:155–162

    Article  CAS  PubMed  Google Scholar 

  39. Calverley PM, Boonsawat W, Cseke Z et al (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912–919

    Article  CAS  PubMed  Google Scholar 

  40. Burge PS, Calverley MA, Jones PW et al (2000) Randomised, placebocontrolled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease; the Isolde trial. Br Med J 320:1297–1303

    Article  CAS  Google Scholar 

  41. Calverley P, Pauwels R, Vestbo J et al (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449–456

    Article  CAS  PubMed  Google Scholar 

  42. Calverley PM, Anderson JA, Celli B et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789

    Article  CAS  PubMed  Google Scholar 

  43. Nannini LJ, Cates CJ, Lasserson TJ, Poole P (2007) Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of systematic reviews 4: CD003794

    Google Scholar 

  44. Karner C, Cates CJ (2011) Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane database of systematic reviews 3: CD008532

    Google Scholar 

  45. Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374:695–703

    Article  CAS  PubMed  Google Scholar 

  46. Calverley PM, Rabe KF, Goehring UM et al (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685–694

    Article  CAS  PubMed  Google Scholar 

  47. Connors AF Jr, Dawson NV, Thomas C et al (1996) Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154:959–967

    Article  PubMed  Google Scholar 

  48. ERS-COPD-audit. www.copdaudit.org (zugegriffen: 30.10.12)

    Google Scholar 

  49. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P et al (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931

    Article  PubMed  PubMed Central  Google Scholar 

  50. Stockley RA, O’Brien C, Pye A, Hill SL (2000) Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117:1638–1645

    Article  CAS  PubMed  Google Scholar 

  51. Report of the Medical Research Council Working Party (1981) Long-term domiciliary oxygen in chronic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1:681–685

    Google Scholar 

  52. Vogelmeier C, Buhl R, Criee CE et al (2007) Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 61:e1–e40

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Wien

About this chapter

Cite this chapter

Geltner, C. (2013). Obstruktive Lungenerkrankungen im Alter – Asthma und COPD. In: Pinter, G., Likar, R., Schippinger, W., Janig, H., Kada, O., Cernic, K. (eds) Geriatrische Notfallversorgung. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1581-7_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-1581-7_24

  • Published:

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-1580-0

  • Online ISBN: 978-3-7091-1581-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics